[Xigris--activated protein C].
Tønnesen
Else K
EK
Arhus Universitetshospital, Arhus Sygehus, Anaestesiologisk-intensiv Afdeling. e.tonnesen@dadlnet.dk
D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009102:Multiple Organ Failure / Q000188:drug therapy; D018579:Patient Selection; D011486:Protein C / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy
D000890:Anti-Infective Agents; D005343:Fibrinolytic Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated